IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Enveric Biosciences Canada Inc	Confirmation No.: 2468
Serial No.:	18/909,368	Group No.:
Filing or 371(c) Date:	October 8, 2024	Examiner: DOCKET CENTRAL

Entitled: Halogenated psilocybin derivatives and methods of using

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application.

1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)
2. Int'l Pat. App. Pub. No. WO/2018/064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)
3. ANGELIS (2002) "5-HT2A antagonists in psychiatric disorders" Current Opinion in Investigational Drugs. Vol 3(1):106-112.

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 18/909,3684 Pending Claims	References
1. A chemical compound or salt thereof having the formula (I):  (I) wherein, at least one of R2, R4, R5, R6 or R7 is a halogen atom, wherein each non-halogenated R2, R5, R6, or R7 is a hydrogen atom or an alkyl group or O-alkyl group, wherein R4 when it is not halogenated is a phosphate group, a hydrogen atom, or an alkyl group or O-alkyl group, and wherein R3a and R3b are a hydrogen atom, an alkyl group, an aryl group, or an acyl group.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...**

	subscript q is an integer from 0 to 3...
2. A chemical compound according to claim 1, wherein R5 is a halogen atom.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be...halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**

3. A chemical compound according to claim 1, wherein R5 is a halogen atom, and wherein each non-halogenated R2, R4, R6, and R7, is a hydrogen atom.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H... R5 of formula (I) can be...halogen...** **R6 of formula (I) can be H...** **and R7 of formula (I) can be H...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
4. A chemical compound according to	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

claim 2, wherein the halogen atom is selected from fluorine (F), chlorine (Cl), and bromine (Br).	From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be...halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...**
5. A chemical compound according to claim 3, wherein the halogen atom is selected from fluorine (F), chlorine (Cl), and bromine (Br).	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H...** **R5 of formula (I) can be...halogen...** **R6 of formula (I) can be H... and R7 of formula (I) can be H...**

	2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
6. A chemical compound according to claim 2, wherein the halogen atom is bromine (Br).	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be...halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...**

	2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
7. A chemical compound according to claim 3, wherein the halogen atom is bromine (Br).	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H...** **R5 of formula (I) can be...halogen...** **R6 of formula (I) can be H...** **and R7 of formula (I) can be H...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

	From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
8. A chemical compound according to claim 1, wherein R3a and R3b are each independently selected from a (C1-C6)-alkyl group and a hydrogen atom.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

	From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
9. A chemical compound according to claim 1, wherein R3a and R3b are each independently selected from a (C1-C6)-alkyl group, and optionally an identical (C1-C6)-alkyl group.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

	From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
10. A chemical compound according to claim 1, wherein R3a and R3b are each independently selected from a (C3-C5)-alkyl group, and optionally, an identical a (C3-C5)-alkyl group.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

	From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
11. A chemical compound according to claim 1, wherein R3a and R3b are each an identical a (C4)-alkyl group.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

	From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
12. A chemical compound according to claim 5, wherein R3a and R3b are each independently selected from a (C1-C6)-alkyl group.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...**
13. A chemical compound according to claim 5, wherein R3a and R3b are each	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018)

independently selected from a (C3-C5)-alkyl group.	From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...**
14. A chemical compound according to claim 5, wherein R3a and R3b are each an identical a (C3-C5)-alkyl group.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H...** **R5 of formula (I) can be...halogen...** **R6 of formula (I) can be H...** **and R7 of formula (I) can be H...**

	2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
15. A chemical compound according to claim 1, having the chemical formula (VIII):  (VIII)	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be...C1-C6-alkyl...** **RN2 of formula (III) can be...C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H...** **R5 of formula (I) can be...halogen...** **R6 of formula (I) can be H...** **and R7 of formula (I) can be H...**

	2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is...di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...**
17. A pharmaceutical drug formulation comprising the chemical compound according to claim 1, together with a pharmaceutically acceptable excipient, diluent, or carrier.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**  From **page 20 line 1: In some embodiments, RN1 of formula (III) can be H, C1-C6-alkyl...** **RN2 of formula (III) can be H, C1-C6-alkyl...** **Ra of formula (I) can be H...** **R4 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R5 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...** **R6 of formula (I) can be H, C1-C6- alkyl...O-(C1-C6-alkyl), halogen...** **and R7 of formula (I) can be H, C1-C6-alkyl...O-(C1-C6-alkyl), halogen...**

	From **page 26 line 14: In some embodiments, oral compositions generally include an inert diluent or an** edible **carrier...the active compound can be incorporated with excipients...** 2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...** From **[0169]: In some embodiments, the present invention provides a pharmaceutical composition including a pharmaceutically acceptable excipient...** From **[0176]: Accordingly, the present invention also provides pharmaceutical compositions including a pharmaceutically acceptable carrier...** From **[0177]: A solid carrier can be one or more substances, which may also act as diluents...**
18. A pharmaceutical drug formulation comprising the chemical compound according to claim 15, together with a pharmaceutically acceptable excipient, diluent, or carrier.	1. Int'l Pat. App. Pub. No. WO/2018/204359 "Compositions and methods for treating ocular pathologies" (Published November 8, 2018) From **page 19 line 5: In embodiments, the composition comprises a compound having the following chemical formula (III):**



From **page 20 line 1: In some embodiments, RN1 of formula (III) can be...C1-C6-alkyl...**
RN2 of formula (III) can be...C1-C6-alkyl...
Ra of formula (I) can be H...
R4 of formula (I) can be H...
R5 of formula (I) can be...halogen...
R6 of formula (I) can be H...
and R7 of formula (I) can be H...

From **page 26 line 14: In some embodiments, oral compositions generally include an inert diluent or an** edible **carrier...the active compound can be incorporated with excipients...**

2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018)

From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**



(IIa)

wherein:
L3 is a bond...
R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...
R9 is hydrogen...
R10 is hydrogen...
R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...
R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...
subscript p is an integer from 0 to 3...
subscript q is an integer from 0 to 3...

From **[0169]: In some embodiments, the present invention provides a pharmaceutical composition including a pharmaceutically acceptable excipient...**

	From **[0176]: Accordingly, the present invention also provides pharmaceutical compositions including a pharmaceutically acceptable carrier...** From **[0177]: A solid carrier can be one or more substances, which may also act as diluents...**
19. A method for treating a psychiatric disorder, the method comprising administering to a subject in need thereof a pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is administered in an effective amount to treat the psychiatric disorder in the subject.	2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...** **R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino...** **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...** From **[0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression, anxiety, and/or post-traumatic stress disorder.**
20. A method according to claim 19, wherein the disorder is a 5-HT2A receptor mediated disorder, and wherein optionally a dose is administered of about 0.001 mg to about 5,000 mg.	2. Int'l Pat. App. Pub. No. WO/2018/2064465 "Compounds for increasing neural plasticity" (Published April 5, 2018) From **Claim 16: The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula IIa...:**  (IIa) **wherein:** **L3 is a bond...** **R8 is hydrogen, halogen, C1-C6 alkyl...C1-C6 alkoxy...** **R9 is hydrogen...** **R10 is hydrogen...**

	R11 is C1-C6 alkylamino, di-(C1-C6 alkyl)amino... **R12 is hydrogen, halogen...C1-C6 alkyl...C1-C6 alkoxy...** **subscript p is an integer from 0 to 3...** **subscript q is an integer from 0 to 3...** From **[0016]: The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for treatment of a brain disorder. The brain disorder can be a psychiatric disorder including depression...** From **[0192]: Suitable dosage ranges include from about 0.1 mg to about 10,000 mg** 3. ANGELIS (2002) "5-HT2A antagonists in psychiatric disorders" Current Opinion in Investigational Drugs. Vol 3(1):106-112. From **Abstract: Several lines of evidence support a role for serotoninergic (5-HT) system abnormalities in the pathogenesis and treatment of several psychiatric disorders. This review summarizes information about the association between the 5-HT2A receptor gene and its relevance to...major depression**

UNITED STATES PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/909,368	**04/22/2025 09:53:36 AM Z ET**	

Title of Invention

Application Information

APPLICATION TYPE		PATENT #	
CONFIRMATION #		FILED BY	Jeremy Rolquin
PATENT CENTER #	70102111	FILING DATE	10/08/2024
CUSTOMER #	–	FIRST NAMED INVENTOR	
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	-

Documents

TOTAL DOCUMENTS: 9

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
third-party-preissuance-submission.pdf		2	Third-Party Submission Under 37 CFR 1.290	49 KB
Third-party-notification-request.pdf		1	Request for Notification of Non-compliant Third-Party Submission	13 KB
Concise-description-generated.pdf		2	Concise Description of Relevance	26 KB
US20250057861 3PS.pdf		19	-	319 KB
US20250057861 3PS-3P.RELEVANCE.pdf	(1-19)	19	Concise Description of Relevance	242 KB
US20250057861 3PS-3P.RELEVANCE.pdf	(1-19)	19	Concise Description of Relevance	242 KB
US20250057861 3PS-3P.RELEVANCE.pdf	(1-19)	19	Concise Description of Relevance	242 KB

1_WO2018204359.pdf		77	-	9662 KB
1_WO2018204359-FOR.pdf	(1-77)	77	Foreign Reference	9662 KB
2_WO2018064465.pdf		85	-	4171 KB
2_WO2018064465-FOR.pdf	(1-85)	85	Foreign Reference	4171 KB
3_5HT2A Antagonists.pdf		7	-	488 KB
3_5HT2A Antagonists-NPL.pdf	(1-7)	7	Non Patent Literature	478 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
third-party-preissuance-submission.pdf	7079B5568C904278ACB63F73BB08F7209C3803787FD64407850627B02190A403214F4D7C7E3FDB6EF83F4E554E82B0D3BF3C3FAF3F760C39DF13121D0AFC37BA
Third-party-notification-request.pdf	21E7BF63B34A8463F5AE86CB64293ACABC90DC772FE60E923EDC482B776C7A0C42A8333817CC17995E60A4A209A4355241FFCBD97276047CE14035E83973923A
Concise-description-generated.pdf	29B4FF3AFAD7AC10754457AA8FA14AF3746CE6D631B2177B43E7CE295CF419076B1D03BFEFE17FB4CF7B653BEC8D559773212BE7B4FC684CFEFB5F98D1A1254F
US20250057861 3PS.pdf	6C5D346D53FD61CB9F96BCC8569C770D697A6746B24519D0C8F0B15DD683D9275144868B00D828836E8A24FA3B8C6B59ACA767A4D5314A84EDCC99BE8B2C0D9D
US20250057861 3PS-3P.RELEVANCE.pdf	DB304A937E12B2DA62C347AE19DEC37B9ABBEDAD9CC63B732189FDAF38A3AB0E56398CA2AEFD3B6A168BEE0E7177B10FFE7D0B36BB6C67569BCEC6AE7330BCF6
US20250057861 3PS-3P.RELEVANCE.pdf	D73F2CB492511A86EB7C77596D6B5B1779FD17F8B5528E0C2CE2A1A7C9AB1FD0A34C5CF164CBA7FFDC88DB6729B596C95B5B5854BA129B7F368D0BED91A2A465
US20250057861 3PS-3P.RELEVANCE.pdf	54CE343142DE468CD7C405514BAB0844DC06AE2DD7D381D6D13085522B6DFC71E137EFC86451FDD80877AC43B2BD66ECB579CEAACD28B7088F5689E057E610BB
1_WO2018204359.pdf	952CEFF3D8B423D5124B71B7D301BBB13A9636EF5305340DFF15DC789FA718A280216C885300CCBCD107A2C85E756ACDE176882A3713826752186EECDB2CAD51
1_WO2018204359-FOR.pdf	9F252CE555976DF631098AD06EC1D5EE9ECC8D1EF5480BF7

	164C5E22BF66D0A8EEB261149A7F2FDCE98CDC2DB639888C C39F96D5E29406A68C1ED188A05D2FE7
2_WO2018064465.pdf	9BD168500D2B00CF2A06DAD2670659817A1F0CE5C4167586A A4BDECD118EB1BD3770927036487F57446232CEF253CDE65 AC7D8D581D6C7605754702E9642B922
2_WO2018064465-FOR.pdf	BC7E82365DAD36EB8946A32DA5ECB3F7015F8949C1CA5900 53F47DC7460EF3E79A150593AC3047DFEE94AB93F53485346 C6E340437A02B7F865B93A88968D60C
3_5HT2A Antagonists.pdf	874F91AA1FDCFE69E8E766A6C811F2EE529AEB732EE88575 EC7926292B64EEBEA18640EDE3E80469B08ECB4944CC530C C2460A71A59C6282ADF05626270146A6
3_5HT2A Antagonists-NPL.pdf	2B79A9D2873047D243EE66FC78A2C1B3F9899F97C5E5CF5AE D4A5A1E7AD677050593168FF20CE6EFEA51B5EB2E5333DC6 E8D2F3278AC7F132C628DD2BC002026

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.